open access

Vol 88, No 4 (2017)
Review paper
Published online: 2017-04-28
Get Citation

Triple negative endometrial cancer

Michał Bulsa, Elżbieta Urasińska
DOI: 10.5603/GP.a2017.0040
·
Pubmed: 28509323
·
Ginekol Pol 2017;88(4):212-214.

open access

Vol 88, No 4 (2017)
REVIEW PAPERS Gynecology
Published online: 2017-04-28

Abstract

Endometrial cancer (EC) is the most common malignancy of the female genital tract in the developed countries. In Poland, EC incidence increased from 3.496 to 5.251 between 2000 and 2011, with 5.251 new cases were diagnosed in 2011 alone, and this upward trend is expected to continue. There are two types of endometrial cancer: estrogen- related type I (approximately 80% of the cases) and unrelated to estrogen type II. Type I includes adenocarcinomas which grow slowly, have better prognosis, superficially infiltrate the myometrium, originate from endometrial hyperplasia without atypia, and occur before and after menopause. The most common type I mutations include PTEN, KRAS and microsatellite instability. Type II is represented by serous, mucinous, clear-cell carcinomas, with aggressive behavior associated with poor prognosis, high risk of distant metastases at diagnosis, deeper infiltration of the uterine muscle, often to serosa, originating from the atrophic endometrium, and typically presenting after menopause. The most common type II mutations include TP53, HER-2 and P16.

Abstract

Endometrial cancer (EC) is the most common malignancy of the female genital tract in the developed countries. In Poland, EC incidence increased from 3.496 to 5.251 between 2000 and 2011, with 5.251 new cases were diagnosed in 2011 alone, and this upward trend is expected to continue. There are two types of endometrial cancer: estrogen- related type I (approximately 80% of the cases) and unrelated to estrogen type II. Type I includes adenocarcinomas which grow slowly, have better prognosis, superficially infiltrate the myometrium, originate from endometrial hyperplasia without atypia, and occur before and after menopause. The most common type I mutations include PTEN, KRAS and microsatellite instability. Type II is represented by serous, mucinous, clear-cell carcinomas, with aggressive behavior associated with poor prognosis, high risk of distant metastases at diagnosis, deeper infiltration of the uterine muscle, often to serosa, originating from the atrophic endometrium, and typically presenting after menopause. The most common type II mutations include TP53, HER-2 and P16.

Get Citation

Keywords

triple negative phenomen; endometrial cancer; triple negative endometrial cancer

About this article
Title

Triple negative endometrial cancer

Journal

Ginekologia Polska

Issue

Vol 88, No 4 (2017)

Article type

Review paper

Pages

212-214

Published online

2017-04-28

DOI

10.5603/GP.a2017.0040

Pubmed

28509323

Bibliographic record

Ginekol Pol 2017;88(4):212-214.

Keywords

triple negative phenomen
endometrial cancer
triple negative endometrial cancer

Authors

Michał Bulsa
Elżbieta Urasińska

References (32)
  1. Bidziński M, Dańska-Bidzińska N. Nowotwory endometrium. In: Spaczyński M, Nowak-Markwitz E, Kędzia W. ed. Praktyczna ginekologia onkologiczna. Wielkopolskie Towarzystwo Onkologii Ginekologicznej, Poznań 2012: 110–117.
  2. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów. Centrum Onkologii — Instytut im. Marii Skłodowskiej-Curie, 2011. http://onkologia.org.pl/raporty/ (29/05/2014).
  3. Wojciechowska U, Didkowska J, Zatoński W. Nowotwory w Polsce w 2012 roku. Nowotwory. Journal of Oncology. 2013; 63(3): 197–216.
  4. Lee LR, Teng PN, Nguyen H, et al. Progesterone enhances calcitriol antitumor activity by upregulating vitamin D receptor expression and promoting apoptosis in endometrial cancer cells. Cancer Prev Res (Phila). 2013; 6(7): 731–743.
  5. Gottwald L, Kubiak R, Pasz-Walczak G, et al. The value of progesterone and estrogen receptors expression in tissue microarray method in prognosis of patients with endometrioid endometrial cancer. Ginekol Pol. 2013; 84(2): 95–101.
  6. Trovik J, Wik E, Werner HMJ, et al. MoMaTEC study group. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. Eur J Cancer. 2013; 49(16): 3431–3441.
  7. Huvila J, Talve L, Carpén O, et al. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma. Gynecol Oncol. 2013; 130(3): 463–469.
  8. Morrison C, Zanagnolo V, Ramirez N, et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol. 2006; 24(15): 2376–2385.
  9. Grushko TA, Filiaci VL, Mundt AJ, et al. Gynecologic Oncology Group. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008; 108(1): 3–9.
  10. Khalifa MA, Mannel RS, Haraway SD, et al. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol. 1994; 53(1): 84–92.
  11. Ludovini V, Gori S, Colozza M, et al. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol. 2008; 19(5): 883–890.
  12. Ariga R, Zarif A, Korasick J, et al. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J. 2005; 11(4): 278–280.
  13. Jiang Xf, Tang Ql, Shen Xm, et al. Tumor-associated macrophages, epidermal growth factor receptor correlated with the triple negative phenotype in endometrial endometrioid adenocarcinoma. Pathol Res Pract. 2012; 208(12): 730–735.
  14. Kothari R, Morrison C, Richardson D, et al. The prognostic significance of the triple negative phenotype in endometrial cancer. Gynecol Oncol. 2010; 118(2): 172–175.
  15. Voss MA, Gordon N, Maloney S, et al. Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer. Br J Cancer. 2011; 104(10): 1611–1618.
  16. Altundag O, Dursun P, Roach EC, et al. Triple negative endometrial cancer may be more sensitive to platinum based chemotherapy. J BUON. 2013; 18(1): 289.
  17. Chacón RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res. 2010; 12 Suppl 2: S3.
  18. Liu N, Wang X, Sheng X. The clinicopathological characteristics of 'triple-negative' epithelial ovarian cancer. J Clin Pathol. 2010; 63(3): 240–243.
  19. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000; 92(11): 924–930.
  20. Dedes KJ, Wetterskog D, Mendes-Pereira AM, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med. 2010; 2(53): 53ra75.
  21. Zhou C, Bae-Jump VL, Whang YE, et al. The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels. Gynecol Oncol. 2006; 101(2): 305–310.
  22. Kiliańska Z, Żołnierczyk J, Węsierska-Gądek J. Biologiczna aktywność polimerazy poli(ADP-rybozy)-1. Postepy Hig Med Dosw. 2010; 64: 344–363.
  23. Domagala P, Huzarski T, Lubinski J, et al. PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. Breast Cancer Res Treat. 2011; 127(3): 861–869.
  24. ClinicalTrials.gov U.S. National Institutes of Health. Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel. http://www.clinicaltrials.gov/ct2/show/NCT00516724 (01/04/2015).
  25. ClinicalTrials.gov U.S. National Institutes of Health. AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer. http://www.clinicaltrials.gov/ct2/show/NCT00647062 (01/04/2015).
  26. Zagouri F, Bozas G, Kafantari E, et al. Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? Obstet Gynecol Int. 2010; 2010: 749579.
  27. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000; 92(11): 924–930.
  28. Risinger JI, Hayes K, Maxwell GL, et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res. 1998; 4(12): 3005–3010.
  29. Blanco-Aparicio C, Renner O, Leal JFM, et al. PTEN, more than the AKT pathway. Carcinogenesis. 2007; 28(7): 1379–1386.
  30. Gadducci A, Cosio S, Genazzani AR. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol. 2006; 58(3): 242–256.
  31. Łapińska-Szumczyk SM, Supernat AM, Majewska HI, et al. Immunohistochemical characterisation of molecular subtypes in endometrial cancer. Int J Clin Exp Med. 2015; 8(11): 21981–21990.
  32. Kwon MJ, Park S, Choi JY, et al. Clinical significance of CD151 overexpression in subtypes of invasive breast cancer. Br J Cancer. 2012; 106(5): 923–930.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl